Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines

International Journal of Cancer

Volumn 110, Issue 3, 2004, Pages 352-361

  Welsh, Carey ^a   Day, Roger ^a,b   McGurk, Claire ^c   Masters, John R W ^c   Wood, Richard D ^a,d   Köberle, Beate ^a,d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

DNA repair protein; ERCC1; Testis tumor cell line; XPA; XPF

Indexed keywords

CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PROTEIN; PROTEIN XPA; PROTEIN XPF; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; EXCISION REPAIR; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; LUNG CANCER; METASTASIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; RAT; TESTIS CANCER; UTERINE CERVIX CANCER;

CELL LINE, TUMOR; DNA REPAIR; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOBLOTTING; LEAST-SQUARES ANALYSIS; MALE; NEOPLASM METASTASIS; TESTICULAR NEOPLASMS; TESTIS; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 2442419814     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20134     Document Type: Article

References (68)

1. Rick O, Siegert W, Beyer J. Chemotherapy in patients with metastatic or relapsed germ-cell tumours. Cancer Treat Rev 2001;27:283-8.
2. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002;99:4592-5.
3. Masters JR, Osborne EJ, Walker MC, Parris CN. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int J Cancer 1993;53:340-6.
4. Parris CN, Arlett CF, Lehmann AR, Green MH, Masters JR. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int J Radiat Biol 1988;53:599-608.
5. Walker MC, Parris CN, Masters JR. Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs. J Natl Cancer Inst 1987;79:213-6.
6. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-41.
7. Zamble DB, Jacks T, Lippard SJ. p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 1998;95:6163-8.
8. Takata M, Sasaki MS, Tachiiri S, Fukushima T, Sonoda E, Schild D, Thompson LH, Takeda S. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 2001;21:2858-66.
9. Tebbs RS, Zhao Y, Tucker JD, Scheerer JB, Siciliano MJ, Hwang M, Liu N, Legerski RJ, Thompson LH. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA-repair gene. Proc Natl Acad Sci USA 1995;92:6354-8.
10. Mello JA, Acharya S, Fishel R, Essigmann JM. The mismatch-repair protein hMSH2 binds selectively to DNA-adducts of the anticancer drug cisplatin. Chem Biol 1996;3:579-89.
11. Massey A, Offman J, Macpherson P, Karran P. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. DNA Repair (Amst) 2003;2:73-89.
12. Vaisman A, Chaney SG. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 2000;275:13017-25.
13. Jansen JG, de Wind N. Biological functions of translesion synthesis proteins in vertebrates. DNA Repair (Amst) 2003;2:1075-85.
14. Wood RD, Araújo SJ, Ariza RR, Batty DP, Biggerstaff M, Evans E, Gaillard P-H, Gunz D, Köberle B, Kuraoka I, Moggs JG, Sandall JK, et al. DNA damage recognition and nucleotide excision repair in mammalian cells. Cold Spring Harbor Symp Quant Biol 2000;65:173-82.
15. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 1997;70:551-5.
16. Köberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999;9:273-6.
17. Rapic Otrin V, Kuraoka I, Nardo T, McLenigan M, Eker AP, Stefanini M, Levine AS, Wood RD. Relationship of the xeroderma pigmentosum group E DNA repair defect to the chromatin and DNA binding proteins UV-DDB and replication protein A. Mol Cell Biol 1998;18:3182-90.
18. Wold MS. Replication protein A: a heterotrimeric single-stranded DNA binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem 1997;66:61-92.
19. Kenny MK, Schlegel U, Furneaux H, Hurwitz J. The role of human single-stranded DNA binding protein and its individual subunits in simian virus 40 DNA replication. J Biol Chem 1990;265:7693-700.
20. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, Rademakers S, de Rooij J, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 1996;86:811-22.
21. Conover WJ. Practical nonparametric statistics, 2nd ed. New York: Wiley, 1980.
22. Hsu JC. The factor analytic approach to simultaneous confidence intervals for multiple comparisons with the best. J Comput Stat Graphics 1992;1:151-68.
23. Hsu JC. Multiple comparisons: theory and methods. London: Chapman and Hall, 1996.
24. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998;273:23419-25.
25. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, Bostick-Bruton F, Reed E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645-52.
26. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000;60:1305-13.
27. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001;48:398-406.
28. Damia G, Guidi G, D'Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur J Cancer 1998;34:1783-8.
29. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
30. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-7.
31. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94:703-8.
32. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
33. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19:4298-304.
34. Codegoni AM, Broggini M, Pitelli MR, Pantarotto M, Torri V, Mangioni C, D'Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 1997;65:130-7.
35. Yagi T, Matsumura Y, Sato M, Nishigori C, Mori T, Sijbers AM, Takebe H. Complete restoration of normal DNA repair characteristics in group F xeroderma pigmentosum cells by over-expression of transfected XPF cDNA. Carcinogenesis 1998;19:55-60.
36. Biggerstaff M, Szymkowski DE, Wood RD. Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J 1993;12:3685-92.
37. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89:453-7.
38. Bronson DL, Andrews PW, Solter D, Cervenka L, Lange PH, Fraley EE. Cell line derived from a metastasis of a human testicular germ cell tumor. Cancer Res 1980;40:2500-6.
39. Pera MF, Friedlos F, Mills J, Roberts JJ. Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. Cancer Res 1987;47:6810-3.
40. Wang X, Hafezparast M, Masters JRW. Complementation analysis of testis tumor cells. Cancer Genet Cytogenet 1997;98:56-62.
41. Hogan B, Fellous M, Avner P, Jacob F. Isolation of a human teratoma cell line which expresses F9 antigen. Nature 1977;270:515-8.
42. Vogelzang NJ, Fraley EE, Lange PH, Torkelson J, Levitt S, Kennedy BJ. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983;1:171-8.
43. Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl Cancer Inst Monogr 1978:49:5-9.
44. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 1973;11:765-73.
45. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosome pattern and ultrastructure. Br J Cancer 1970;24:746-54.
46. Masters JR, Hepburn PJ. Human bladder cancer in vitro drug sensitivities: range and stability in long-term culture. Br J Cancer 1986;54:131-5.
47. Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P. Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 1977;58:881-90.
48. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
49. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU145). Int J Cancer 1978;21:274-81.
50. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-32.
51. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
52. Engel LW, Young NA, Tralka TS, Lippman ME, O'Brien SJ, Joyce MJ. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res 1978;38:3352-64.
53. Cailleau R, Young R, Olive M, Reeves WJ Jr. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974;53:661-74.
54. Gazdar AF, Minna JD. Cell lines as an investigational tool for the study of biology of small cell lung cancer. Eur J Cancer Clin Oncol 1986;22:909-11.
55. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983;306:194-6.
56. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
57. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-23.
58. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221-6.
59. Siegfried JM. Culture of primary lung tumors using medium conditioned by a lung carcinoma cell line. J Cell Biochem 1989;41:91-5.
60. Chen TR. Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes. Cytogenet Cell Genet 1988;48:19-24.
61. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 1985;119:361-6.
62. Friedl F, Kimura I, Osato T, Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 1970;135:543-5.
63. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF. Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science 1977;196:1456-8.
64. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, Harrap KR. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 1989;59:527-34.
65. Pattillo RA, Hussa RO, Garancis JC. Glycogen metabolism in human hormone-producing trophoblastic cells in continuous culture. I. Regulation of glycogen metabolism by glucose. In Vitro 1971;7:59-67.
66. Tainsky MA, Krizman DB, Chiao PI, Yim SO, Giovanella BC. PA-1, a human cell model for multistage carcinogenesis: oncogenes and other factors. Anticancer Res 1988;8:899-913.
67. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972;49:891-5.
68. Iakoucheva LM, Kimzey AL, Masselon CD, Smith RD, Dunker AK, Ackerman EJ. Aberrant mobility phenomena of the DNA repair protein XPA. Protein Sci 2001;10:1353-62.